Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners
Determined the primary chemoresistance markers (expression of genes ERCC1, TOP2a and ABCB1) in epithelial cells of ascites 32 primary patients with verified ovarian cancer using RT-PCR. After standard chemotherapy by the AR scheme (cisplatin+doxoru-bicin), the relapse-free survival of patients was a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2020-05-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063383287562240 |
|---|---|
| author | D. R. Dolgova T. P. Gening T. V. Abakumova S. O. Gening I. I. Antoneeva A. B. Pescov A. Yu. Fedotova |
| author_facet | D. R. Dolgova T. P. Gening T. V. Abakumova S. O. Gening I. I. Antoneeva A. B. Pescov A. Yu. Fedotova |
| author_sort | D. R. Dolgova |
| collection | DOAJ |
| description | Determined the primary chemoresistance markers (expression of genes ERCC1, TOP2a and ABCB1) in epithelial cells of ascites 32 primary patients with verified ovarian cancer using RT-PCR. After standard chemotherapy by the AR scheme (cisplatin+doxoru-bicin), the relapse-free survival of patients was assessed by Kaplan-Mayer. Patients with early (up to 6 months) and late (more than 6 months) relapse were isolated. As a result of the conducted studies it was established that early relapse occurred in 67% of the examined patients (the relapse-free period was 88.7+13.3 days). At the same time, in the groups with increased expression, the relapse-free period did not differ significantly, there were early relapses. The use of the Cochrane Q-test has allowed to establish that the reduced levels of ERCC1 and ABCB1, the proportion of survivors is to 72.7% (p |
| format | Article |
| id | doaj-art-e58c3aecc59f4f5c8e3eecf7c8de729d |
| institution | DOAJ |
| issn | 0235-2990 |
| language | Russian |
| publishDate | 2020-05-01 |
| publisher | LLC "Publishing House OKI" |
| record_format | Article |
| series | Антибиотики и Химиотерапия |
| spelling | doaj-art-e58c3aecc59f4f5c8e3eecf7c8de729d2025-08-20T02:49:36ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-05-01645-6182110.24411/0235-2990-2019-100026136Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for PractitionersD. R. Dolgova0T. P. Gening1T. V. Abakumova2S. O. Gening3I. I. Antoneeva4A. B. Pescov5A. Yu. Fedotova6Ulyanovsk State UniversityUlyanovsk State UniversityUlyanovsk State UniversityUlyanovsk State UniversityUlyanovsk State UniversityUlyanovsk State UniversityUlyanovsk State UniversityDetermined the primary chemoresistance markers (expression of genes ERCC1, TOP2a and ABCB1) in epithelial cells of ascites 32 primary patients with verified ovarian cancer using RT-PCR. After standard chemotherapy by the AR scheme (cisplatin+doxoru-bicin), the relapse-free survival of patients was assessed by Kaplan-Mayer. Patients with early (up to 6 months) and late (more than 6 months) relapse were isolated. As a result of the conducted studies it was established that early relapse occurred in 67% of the examined patients (the relapse-free period was 88.7+13.3 days). At the same time, in the groups with increased expression, the relapse-free period did not differ significantly, there were early relapses. The use of the Cochrane Q-test has allowed to establish that the reduced levels of ERCC1 and ABCB1, the proportion of survivors is to 72.7% (phttps://www.antibiotics-chemotherapy.ru/jour/article/view/137ovarian cancerascitesdrug resistance genesrelapse-free survival |
| spellingShingle | D. R. Dolgova T. P. Gening T. V. Abakumova S. O. Gening I. I. Antoneeva A. B. Pescov A. Yu. Fedotova Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners Антибиотики и Химиотерапия ovarian cancer ascites drug resistance genes relapse-free survival |
| title | Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners |
| title_full | Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners |
| title_fullStr | Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners |
| title_full_unstemmed | Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners |
| title_short | Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners |
| title_sort | markers of primary chemoresistance of epithelial ascites cells in patients with ovarian cancer guidelines for practitioners |
| topic | ovarian cancer ascites drug resistance genes relapse-free survival |
| url | https://www.antibiotics-chemotherapy.ru/jour/article/view/137 |
| work_keys_str_mv | AT drdolgova markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners AT tpgening markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners AT tvabakumova markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners AT sogening markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners AT iiantoneeva markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners AT abpescov markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners AT ayufedotova markersofprimarychemoresistanceofepithelialascitescellsinpatientswithovariancancerguidelinesforpractitioners |